CardieX Limited provided revenue guidance for the fiscal year 2023. At this stage group revenue for fiscal year 2023 is expected to be more than 7% up on the revenues achieved in fiscal year 2022 excluding any potential acceleration of Clinichain revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.066 AUD | 0.00% | +22.22% | -51.11% |
04-02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
04-02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.11% | 12.95M | |
+11.18% | 225B | |
+15.22% | 197B | |
+19.19% | 143B | |
+30.89% | 111B | |
+1.67% | 64.72B | |
+18.48% | 54.44B | |
+5.12% | 51.06B | |
+10.53% | 45.03B | |
+5.98% | 37.4B |
- Stock Market
- Equities
- CDX Stock
- News CardieX Limited
- CardieX Limited Provides Revenue Guidance for the Fiscal Year 2023